Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     
  • Bitcoin GBP

    50,492.36
    -1,127.30 (-2.18%)
     
  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

TMO’s Oncomine Dx Target Test Gets CMS Coverage

On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).